BOLT
- Bolt Biotherapeutics, Inc.
()
Overview
Company Summary
Bolt Biotherapeutics, Inc. (BOLT) is a biotechnology company that specializes in developing innovative cancer therapies. The company focuses on leveraging the power of immune-stimulating antibody conjugates (ISACs) in order to target and eradicate tumors.
Bolt Biotherapeutics' primary technology, ISAC, combines the precision targeting capabilities of antibodies with the potent immune response of toll-like receptor (TLR) agonists. By linking TLR agonists to tumor-targeting antibodies, ISACs are designed to specifically deliver immune-stimulating agents directly to cancer cells.
The unique approach used by Bolt Biotherapeutics aims to enhance the overall effectiveness of cancer immunotherapy. By activating the body's immune response at the tumor site, ISACs have the potential to enhance the recognition and elimination of cancer cells while minimizing off-target effects.
Bolt Biotherapeutics is committed to advancing its pipeline of ISAC-based drug candidates to address unmet medical needs across various cancer indications. The company's research and development efforts are focused on preclinical and clinical studies, evaluating the safety, efficacy, and therapeutic potential of its innovative ISAC technology.
Overall, Bolt Biotherapeutics aims to revolutionize cancer treatment by developing novel therapies that harness the immune system's natural ability to recognize and destroy cancer cells.